Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Cardiol Therapeutics ( (TSE:CRDL) ).
In its year-end 2025 operational update released on April 1, 2026, Cardiol Therapeutics reported strong clinical and strategic progress centered on its CardiolRx program. The company initiated the pivotal Phase III MAVERIC trial in recurrent pericarditis in April 2025, surpassed 50% patient enrollment with completion expected in the second quarter of 2026, and highlighted that positive Phase II ARCHER data in acute myocarditis, published in ESC Heart Failure in February 2026, demonstrated significant reductions in left ventricular mass and improvements in cardiac structure.
Cardiol also advanced its CRD-38 program through IND-enabling work in 2025 toward a Phase I trial for inflammatory heart diseases, broadened its U.S. intellectual property with a patent allowance extending protection for CardiolRx and CRD-38 across multiple cardiac indications to October 2040, and strengthened governance with the May 2025 election of former Eli Lilly chief medical officer Dr. Timothy Garnett to its board. The company raised $31 million in gross proceeds during the year, providing funding through the expected completion of MAVERIC and into the fourth quarter of 2027, which bolsters its ability to reach key value milestones and potentially reinforce its position in emerging treatments for inflammation-driven heart disease.
The most recent analyst rating on (TSE:CRDL) stock is a Buy with a C$9.00 price target. To see the full list of analyst forecasts on Cardiol Therapeutics stock, see the TSE:CRDL Stock Forecast page.
Spark’s Take on CRDL Stock
According to Spark, TipRanks’ AI Analyst, CRDL is a Neutral.
The score is held down primarily by very weak financial performance (pre-revenue profile, large ongoing losses, and substantial cash burn with shrinking equity), which increases financing and dilution risk despite low debt. Technicals provide only a modest offset due to improving short-term momentum, while valuation remains unattractive because the company is loss-making and offers no dividend support.
To see Spark’s full report on CRDL stock, click here.
More about Cardiol Therapeutics
Cardiol Therapeutics Inc. is a late-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease. Its lead drug candidate, CardiolRx, targets inflammatory cardiac conditions such as recurrent pericarditis and acute myocarditis, while its next-generation agent CRD-38 is being advanced for heart failure and other inflammatory heart diseases.
Average Trading Volume: 105,028
Technical Sentiment Signal: Buy
Current Market Cap: C$211.1M
Learn more about CRDL stock on TipRanks’ Stock Analysis page.